Enanta Pharmaceuticals
ENTA
54 hedge funds and large institutions have $87.3M invested in Enanta Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
43% more capital invested
Capital invested by funds: $60.9M → $87.3M (+$26.4M)
31% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 13
29% more funds holding
Funds holding: 42 → 54 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$10.9M |
| 2 |
B
Bailard
Foster City,
California
|
+$2.49M |
| 3 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
+$1.53M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$1.03M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$971K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.72M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$2.72M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.94M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$803K |
| 5 |
Morgan Stanley
New York
|
-$773K |
ENTA Hedge Fund Activity: Q3 2013 in Review
54 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2013, worth a combined $87.3M — up 43% from $60.9M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ENTA positions and 6 closed out — a net gain of 12 holders — while 17 added to existing stakes and 13 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $10.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.72M sold.
- 54 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2013, up from 42 in Q2 2013.
- Funds reported $87.3M of Enanta Pharmaceuticals stock for Q3 2013, up 43% quarter-over-quarter.
- 18 funds opened new Enanta Pharmaceuticals positions in Q3 2013 and 6 closed out, a net change of +12 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2013 was Consonance Capital Management, an estimated $10.9M added.
- The largest Enanta Pharmaceuticals seller in Q3 2013 was RA Capital Management, an estimated $7.72M sold.
Based on aggregated 13F filings for Q3 2013.